Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis

Mult Scler Relat Disord. 2022 Feb:58:103524. doi: 10.1016/j.msard.2022.103524. Epub 2022 Jan 11.

Abstract

Background: The impact of disease-modifying treatments on humoral response induced by inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is understudied.

Methods: We recruited 34 persons with multiple sclerosis (MS) under fingolimod treatment and 25 healthy individuals. Anti-SARS-CoV-2 spike IgG indices were measured by ELISA in sera of participants after CoronaVac vaccinations.

Results: Persons with MS displayed significantly lower antibody levels and seropositivity prevalence. Persons with MS with longer fingolimod treatment durations displayed lower anti-SARS-CoV-2 indices.

Conclusion: Our results support previous findings regarding humoral response impairing effect of fingolimod after vaccinations. Patients under fingolimod treatment may require closer monitoring for COVID-19.

Keywords: COVID-19; CoronaVac; Fingolimod; Multiple sclerosis; SARS-COV-2; Vaccination.

Publication types

  • Letter

MeSH terms

  • Antibodies, Viral
  • Antibody Formation
  • COVID-19* / prevention & control
  • Fingolimod Hydrochloride / therapeutic use
  • Humans
  • Multiple Sclerosis* / drug therapy
  • SARS-CoV-2
  • Spike Glycoprotein, Coronavirus
  • Vaccination
  • Vaccines, Inactivated

Substances

  • Antibodies, Viral
  • Spike Glycoprotein, Coronavirus
  • Vaccines, Inactivated
  • spike protein, SARS-CoV-2
  • Fingolimod Hydrochloride